Assistant Editor: Special Assignments
JULIA AALBERS
TEL: 021 976 8129
e-mail:
Development Editor:
GLENDA HARDY
TEL: 021 976 8129
CELL: 071 819 6425
FAX: 086 610 3395
e-mail:
Production Editor
SHAUNA GERMISHUIZEN
TEL: 021 785 7178
FAX: 086 628 1197
e-mail:
Production Co-ordinator
WENDY WEGENER
TEL: 021 976 8129
e-mail:
Editorial Assistant and Circulation
ELSABÉ BURMEISTER
TEL: 021 976 8129
FAX: 086 664 4202
e-mail:
Gauteng Contributor
PETER WAGENAAR
CELL: 082 413 9954
e-mail:
Content Manager
MICHAEL MEADON
(Design Connection)
TEL: 021 976 8129
FAX: 086 655 7149
e-mail:
The
South African Journal of Dia-
betes and Vascular Disease
is pub-
lished four times a year for Clinics
Cardive Publishing (Pty) Ltd and
printed by Durbanville Commercial
Printers. Online Services: Design
Connection.
Articles in this Journal are sourced
as per agreement with the British
Journal of Diabetes and Vascular
Disease
All correspondence to be directed to:
THE EDITOR
PO BOX 1013
DURBANVILLE
7551
or
TEL: 021 976 8129
FAX: 086 664 4202
INT: 2721 976-8129
To subscribe to the journal or
change address, email
Full text articles available on:
via
The opinions, data and statements that
appear in any articles published in this
journal are those of the contributors.
The publisher, editors and members of
the editorial board do not necessarily
share the views expressed herein.
Although every effort is made to
ensure accuracy and avoid mistakes,
no liability on the part of the publisher,
editors, the editorial board or their
agents or employees is accepted for
the consequences of any inaccurate or
misleading information.
Diabetes News
35
Changing dietary habits and associated
nutritional deficiencies impact on urban
African patients living with heart failure
in Soweto
P Wagenaar
36
South African studies in the international
literature: considerations of ethnicity and
gender in chronic diseases of lifestyle
G Hardy
Drug Trends
39
Sanofi diabetes specialist weekend 2012,
Cape Town
G Hardy
43
Second-generation sulphonylureas:
gliclazide modified release (60 mg)
reviewed in clinical practice for type 2
diabetes
J Aalbers
Page 11
Page 32
:H DUH SOHDVHG WR DQQRXQFH WKDW WKH 6(0'6$ /$66$ &RQJUHVV
LQFRUSRUDWLQJ WKH '(66$ :RUN
VKRS ZLOO EH KHOG DW WKH :DQGHUHUV &OXE ,OORYR -RKDQQHVEXUJ IURP WKH WK $SULO
WR WKH VW $SULO
:H KDYH EHHQ IRUWXQDWH LQ VHFXULQJ WKH SDUWLFLSDWLRQ RI D QXPEHU RI HPLQHQW RYHUVHDV H[SHUWV LQ WKH ÀHOGV
RI GLDEHWHV PHOOLWXV JHQHUDO HQGRFULQRORJ\ DQG OLSLGRORJ\ 7KH FRQJUHVV ZLOO LQFOXGH DQ H[FLWLQJ OLQH XS RI
SOHQDU\ DQG PHHW WKH SURIHVVRU VHVVLRQV GHEDWHV RUDO DQG SRVWHU SUHVHQWDWLRQV
7KH SUH 6(0'6$ PHHWLQJ ² (1'2 ² ZLOO EH KHOG RQ 7KXUVGD\ WK $SULO
6(0'6$ ZLOO EHJLQ RQ )ULGD\ WK $SULO
DQG '(66$ ZLOO KROG WKHLU ZRUNVKRS LQ SDUDOOHO
/$66$ ZLOO EH KHOG RQ 6XQGD\ VW $SULO
$EVWUDFWV PD\ EH VXEPLWWHG HOHFWURQLFDOO\ WR VKHOOH\#VHPGVD RUJ ]D
$OO GHWDLOV FDQ EH IRXQG RQ RXU ZHEVLWH ZZZ VHPGVD RUJ ]D XQGHU
&RQJUHVV
5HJLVWUDWLRQ IRUPV WRJHWKHU ZLWK WKH UHOHYDQW IHHV PXVW EH IRUZDUGHG WR WKH 6(0'6$ RIÀFH
3OHDVH QRWH
'HDGOLQH IRU UHFHLSW RI WKH IRUPV LQFOXGLQJ DEVWUDFWV LV )(%58$5<
:H ORRN IRUZDUG WR ZHOFRPLQJ \RX WR RXU VWLPXODWLQJ FRQJUHVV LQ -RKDQQHVEXUJ LQ $SULO
6(0'6$ /$66$ &21*5(66
